Cutaneous Lupus Erythematosus Clinical Trials

A listing of Cutaneous Lupus Erythematosus medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

 

Alabama

UPDATED

Contact LILAC Research Site Directly
Anniston Alabama 36207

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

Research Center
Anniston Alabama 36207

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

View More ▼

Anniston Alabama 36207

Patients are needed to participate in a clinical research study evaluating BIIB059 and Placebo for the treatment of Systemic Lupus Erythematosus (SLE) or Active Cutaneous Lupus Erythematosus (CLE)

California

UPDATED

Contact LILAC Research Site Directly
La Mesa California 91942

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

Research Center
La Mesa California 91942

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

UPDATED

Contact LILAC Research Site Directly
Los Angeles California 90045

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

Research Center
Los Angeles California 90045

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

UPDATED

Contact LILAC Research Site Directly
Upland California 91786

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

Research Center
Upland California 91786

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

View More ▼

Los Angeles California 90045

Patients are needed to participate in a clinical research study evaluating BIIB059 and Placebo for the treatment of Systemic Lupus Erythematosus (SLE) or Active Cutaneous Lupus Erythematosus (CLE)

Upland California 91786

Patients are needed to participate in a clinical research study evaluating BIIB059 and Placebo for the treatment of Systemic Lupus Erythematosus (SLE) or Active Cutaneous Lupus Erythematosus (CLE)

West Hollywood California 90048

Patients are needed to participate in a clinical research study of Milatuzumab

Georgia

UPDATED

Contact LILAC Research Site Directly
Sandy Springs Georgia 30328

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

Research Center
Sandy Springs Georgia 30328

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

View More ▼

Atlanta Georgia 30342

Patients are needed to participate in a clinical research study evaluating BIIB059 and Placebo for the treatment of Systemic Lupus Erythematosus (SLE) or Active Cutaneous Lupus Erythematosus (CLE)

Indiana

Research Center
Indianapolis Indiana 46256

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

UPDATED

Contact LILAC Research Site Directly
Indianapollis Indiana 46256

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

View More ▼

Indianapolis Indiana 46256

Patients are needed to participate in a clinical research study evaluating BIIB059 and Placebo for the treatment of Systemic Lupus Erythematosus (SLE) or Active Cutaneous Lupus Erythematosus (CLE)

New York

NEW

Research Center
Great Neck New York 11021

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

View More ▼

Great Neck New York 11020

Patients are needed to participate in a clinical research study evaluating BIIB059 and Placebo for the treatment of Systemic Lupus Erythematosus (SLE) or Active Cutaneous Lupus Erythematosus (CLE)

North Carolina

UPDATED

Contact LILAC Research Site Directly
Charlotte North Carolina 28207

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

UPDATED

Contact LILAC Research Site Directly
Charlotte North Carolina 28204

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

Research Center
Charlotte North Carolina 28204

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

Research Center
Charlotte North Carolina 28207

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

UPDATED

Contact LILAC Research Site Directly
Wilmington North Carolina 28401

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

Research Center
Wilmington North Carolina 28401

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

View More ▼

Charlotte North Carolina 28204

Patients are needed to participate in a clinical research study evaluating BIIB059 and Placebo for the treatment of Systemic Lupus Erythematosus (SLE) or Active Cutaneous Lupus Erythematosus (CLE)

Wilmington North Carolina 28401

Patients are needed to participate in a clinical research study evaluating BIIB059 and Placebo for the treatment of Systemic Lupus Erythematosus (SLE) or Active Cutaneous Lupus Erythematosus (CLE)

Ohio

Columbus Ohio 43230

Patients are needed to participate in a clinical research study evaluating BIIB059 and Placebo for the treatment of Systemic Lupus Erythematosus (SLE) or Active Cutaneous Lupus Erythematosus (CLE)

Pennsylvania

UPDATED

Contact LILAC Research Site Directly
Duncansville Pennsylvania 16635

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

Research Center
Duncansville Pennsylvania 16635

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

UPDATED

Contact LILAC Research Site Directly
Pittsburgh Pennsylvania 15213

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

Research Center
Pittsburgh Pennsylvania 15213

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

View More ▼

Duncansville Pennsylvania 16635

Patients are needed to participate in a clinical research study evaluating BIIB059 and Placebo for the treatment of Systemic Lupus Erythematosus (SLE) or Active Cutaneous Lupus Erythematosus (CLE)

Pittsburgh Pennsylvania 15213

Patients are needed to participate in a clinical research study evaluating BIIB059 and Placebo for the treatment of Systemic Lupus Erythematosus (SLE) or Active Cutaneous Lupus Erythematosus (CLE)

Texas

UPDATED

Contact LILAC Research Site Directly
Austin Texas 78731

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

Research Center
Austin Texas 78731

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

Virginia

UPDATED

Contact LILAC Research Site Directly
Norfolk Virginia 23502

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

Research Center
Norfolk Virginia 23502

LILAC Study – For Patients with Cutaneous and/or Systemic Lupus

View More ▼

Norfolk Virginia 23507

Patients are needed to participate in a clinical research study evaluating BIIB059 and Placebo for the treatment of Systemic Lupus Erythematosus (SLE) or Active Cutaneous Lupus Erythematosus (CLE)

Germany

Leipzig Saxony 04103

A clinical study for patients with Lupus Erythematosus, Cutaneous or Lupus Erythematosus, Discoid

United Kingdom

Leeds LS7 4SA

A clinical trial seeking patients for a research study for the treatment of Lupus Erythematosus, Discoid, Lupus Erythematosus, Cutaneous or Lupus Erythematosus, Chronic Cutaneous